Wieliczko Monika, Pyrża Michał, Małyszko Jolanta
DEPARTMENT OF NEPHROLOGY, DIALYSIS AND INTERNAL DISEASE, MEDICAL UNIVERSITY OF WARSAW, WARSAW, POLAND.
Wiad Lek. 2020;73(9 cz. 2):2068-2072.
Cancer in dialysis patients is a common problem and is one of the most common reasons of mordibity and mortality in developed countries. An impaired renal function leads to the accumulation in the blood products of nitrogen transformation, which negatively affect organ function, especially the immune system. The Standardized Cancer Incidence is higher in patients with end-stage kidney failure than in the general population and reaches 1,18-1,42. The cancer risk is three times higher in dialysis patients over age 65 years and is more common among hemodialysis than peritoneal dialysis patients. The most common type of cancer occurring in this group of patients is urinary tract cancer which often develops on the basis of acquired cysts and in patients previously treated with cyclophosphamide. Nonetheless, patients with kidney problems are not regularly tested for these diseases and the only group that is screened for cancer are patients tested for kidney transplantation. Some problems in this topic are briefly presented in this article.
透析患者的癌症是一个常见问题,并且是发达国家中发病率和死亡率最高的原因之一。肾功能受损会导致血液中氮转化产物的积累,这会对器官功能产生负面影响,尤其是免疫系统。终末期肾衰竭患者的标准化癌症发病率高于普通人群,达到1.18 - 1.42。65岁以上的透析患者患癌风险高出三倍,并且在血液透析患者中比腹膜透析患者更为常见。在这类患者中最常见的癌症类型是泌尿系统癌症,其通常在获得性囊肿的基础上发生,并且在先前接受过环磷酰胺治疗的患者中更为常见。尽管如此,肾脏问题患者并未定期接受这些疾病的检测,而唯一接受癌症筛查的群体是接受肾移植检测的患者。本文简要介绍了该主题中的一些问题。